2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
June 30th, 2025
Version: 2
The Francis Crick Institute
cancer biology
biorxiv

Vinorelbine enhances the efficacy of GM-CSF-armed oncolytic vaccinia virus in a preclinical model of ovarian high grade serous carcinoma

Drymiotou, S.Open in Google Scholar•Queval, C. J.Open in Google Scholar•Tyson, K. E.Open in Google Scholar•Sheach, L. A.Open in Google Scholar•Postigo, A.Open in Google Scholar•Rosa, I. D.Open in Google Scholar•Ennis, D. P.Open in Google Scholar•Howell, M.Open in Google Scholar•McNeish, I. A.Open in Google Scholar•Way, M.Open in Google Scholar

Vaccinia virus, known for its clinical safety has a tropism for primary and metastatic tumours as well as ovarian tissue. Consequently, oncolytic approaches with recombinant vaccinia viruses have emerged as attractive agents against ovarian cancer. Unfortunately, oncolytic vaccinia monotherapies are yet to live up to their potential promise. Given this, there is a need to identify combination agents that improve the effectiveness of vaccinia in ovarian cancer treatment. We screened 9,000 compounds to identify drugs that enhance the ability of a recombinant vaccinia virus lacking VGF and F1 ({Delta}VF) to induce death of ID8 Trp53-/- murine ovarian cancer cells. We identified a class of tubulin polymerisation inhibitors including vinorelbine. The combination of vinorelbine and vaccinia induces ID8 Trp53-/- cell death via apoptosis. In a syngeneic mouse model of high grade serous ovarian carcinoma, {Delta}VF virus lacking the viral thymidine kinase (TK), armed with GM-CSF and expressing NeonGreen ({Delta}VFTK-NG-GM-CSF) is tumour specific. A combination of the {Delta}VFTK-NG-GM-CSF virus with vinorelbine prolongs mouse survival compared to the treatment of mice with either agent alone. Our study suggests vinorelbine is a promising agent to combine with oncolytic vaccinia virus approaches for the management of ovarian cancer.

Similar Papers

biorxiv
Mon Jun 30 2025
Decoding Breast Cancer Heterogeneity via Multi-Omics Integration and Language Model-Based Interpretation
We present a novel pipeline combining Multi-Omics Factor Analysis (MOFA) and fine-tuned Large Language Models (LLMs) to predict breast cancer subtypes using proteomics, DNA methylation, and RNA-Seq data. Breast cancer is a heterogeneous disease characterized by diverse molecular alterations across multiple biological layers, necessitating integrative approaches for accurate subtype classification....
Yasrab, R.
•
Agrawal, R.
•
Saber-Ayad, M.
•
El-Hadidi, M.
biorxiv
Mon Jun 30 2025
Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology
Accurately predicting which patients will respond to immune checkpoint blockade (ICB) remains a major challenge. Here, we present TIME_ACT, an unsupervised 66-gene transcriptomic signature of tumor immune activation derived from TCGA melanoma data. First, TIME_ACT scores accurately identify tumors with activated immune microenvironments across cancer types. Analysis of spatial features of the tumo...
Mukherjee, S.
•
Patiyal, S.
•
Pal, L. R.
•
Chang, T.
...•
Ruppin, E.
biorxiv
Mon Jun 30 2025
Intratumoral Treg ablation is sufficient to mediate tumor control systemically without autoimmunity
Regulatory T cells (Tregs) infiltrate most tumors, yet whether they suppress immune responses directly within tumor tissues is untested. We used intratumoral (IT) delivery of diphtheria toxin (DT) in Foxp3DTR mice to deplete IT Tregs while leaving peripheral Tregs intact. IT delivery of DT reduced Treg frequencies in the tumor, which promoted potent tumor control without autoimmunity. Interestingl...
Bockman, A.
•
Gittins, B.
•
Zhang, C.
•
Hung, J.
...•
DuPage, M.
biorxiv
Mon Jun 30 2025
CD47 blockade enhances immunoradiotherapy response in head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is a significant cause of morbidity and mortality worldwide, with limited treatment options for patients with locally advanced disease. CD47 immune checkpoint inhibitors have been used to block the CD47/SIRPa interaction that inhibits antigen-presenting cell phagocytosis, thereby enhancing antigen presentation to cytotoxic T-cells, and have shown promi...
Monther, A.
•
Al-Msari, R.
•
Saddawi-Konefka, R.
•
Fassardi, S.
...•
Califano, J.
biorxiv
Mon Jun 30 2025
NK cell co-localization with epithelial cells in pancreatic cancer is influenced by fibroblasts and ECM components
Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive and common type of pancreatic cancer. PDAC has a dense, fibrotic tumor microenvironment (TME) that restricts immune cell infiltration and contributes to poor immunotherapy responses. While T cell-based therapies have been largely ineffective, natural killer (NK) cells-which kill tumor cells without requiring MHC recognition-offer a pro...
Malchiodi, Z. X.
•
Lekan, A. A.
•
Suter, R. K.
•
Deshpande, A.
...•
Weiner, L. M.
biorxiv
Mon Jun 30 2025
Targeting breast cancer senescence in 3D models of bone metastasis
Chemotherapeutic treatment of breast cancer with Doxorubicin can induce tumor and stromal cell senescence leading to therapy-resistance. Senescence-associated secretory phenotype (SASP) promotes secretion of pro-inflammatory and tumorigenic factors causing systemic inflammation. Combined, this can result in immune suppression, tumor growth and secondary spread of cancer. Targeting and removing sen...
Hamburger, E. C. B.
•
Mohseni Garakani, M.
•
Alfaisali, S.
•
Ouellet, J. A.
...•
Rosenzweig, D. H.
biorxiv
Mon Jun 30 2025
Reprogramming of Osimertinib-Resistant EGFR-mutant NSCLC: The Pyruvate-Acetaldehyde-Acetate Pathway As a Key Driver of Resistance
Osimertinib (Osi) resistance remains a significant challenge in EGFR mutant non-small-cell lung cancer (NSCLC). This study investigates the metabolic reprogramming associated with Osi resistance, identifying key metabolic vulnerabilities that may be targeted for therapeutic intervention. Employing the EGFR-mutant H1975 parental (Par) cell line and its Osi-resistant (OsiR) counterpart, we integrate...
Maroni, G.
•
Cabrera San Millan, E.
•
Mercatelli, R.
•
Chiodi, A.
...•
Levantini, E.
biorxiv
Mon Jun 30 2025
Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology
Accurately predicting which patients will respond to immune checkpoint blockade (ICB) remains a major challenge. Here, we present TIME_ACT, an unsupervised 66-gene transcriptomic signature of tumor immune activation derived from TCGA melanoma data. First, TIME_ACT scores accurately identify tumors with activated immune microenvironments across cancer types. Analysis of spatial features of the tumo...
Mukherjee, S.
•
Patiyal, S.
•
Pal, L. R.
•
Chang, T.
...•
Ruppin, E.
biorxiv
Sun Jun 29 2025
Riboflavin drives nucleotide biosynthesis and iron-sulfur metabolism to promote acute myeloid leukemia
Riboflavin is a diet-derived vitamin in higher organisms that serves as a precursor for flavin mononucleotide and flavin adenine dinucleotide, key cofactors that participate in oxidoreductase reactions. Here, using proteomic, metabolomic and functional genomics approaches, we describe a specific riboflavin dependency in acute myeloid leukemia and demonstrate that, in addition to energy production ...
Bjelosevic, S.
•
Fauth, R.
•
Do, B. T.
•
Alexe, G.
...•
Stegmaier, K.